Pleomorphic adenoma is the most common salivary gland tumour out of which 85% arise from parotid gland. It is a slow–growing, benign, mixed tumour having dual nature of origin from epithelial and myoepithelial components. Pleomorphic adenoma can be managed by surgery like superficial or total parotidectomy based on the anatomical location of tumour. Postoperative adjuvant radiation therapy is generally indicated in case of residual disease, close or positive margin, intraoperative tumour spillage, and high-grade and recurrent tumour. Radiotherapy can be given either through interstitial needle brachytherapy or external beam radiotherapy by three-field technique using mixed photon and electron beam. Radiotherapy is generally well tolerated with few side effects like mucositis, dermatitis, xerostomia, altered taste sensation, and rare late toxicity like trismus, hearing loss, osteoradionecrosis of mandible. Newer techniques like IMRT, arc therapy, IGRT help in better normal tissue sparing and reduces toxicities. Furthermore, high LET radiations like proton therapy, carbon ion & neutron therapy can offer superior dose distribution specially in more complex & recurrent cases.